For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
In the latest session, Resmed Inc (NYSE: RMD) closed at $242.55 down -1.38% from its previous closing price of $245.94. In other words, the price has decreased by -$1.38 from its previous closing price. On the day, 1.09 million shares were traded. RMD stock price reached its highest trading level at $247.78 during the session, while it also had its lowest trading level at $241.66.
Ratios:
For a deeper understanding of Resmed Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 25.44 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 20.02. For the most recent quarter (mrq), Quick Ratio is recorded 2.13 and its Current Ratio is at 2.89. In the meantime, Its Debt-to-Equity ratio is 0.14 whereas as Long-Term Debt/Eq ratio is at 0.09.
On September 18, 2025, Citigroup started tracking the stock assigning a Buy rating and target price of $330.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Dec 08 ’25 when Farrell Michael J. sold 4,991 shares for $251.41 per share. The transaction valued at 1,254,796 led to the insider holds 466,223 shares of the business.
Farrell Michael J. bought 4,991 shares of RMD for $1,254,796 on Dec 08 ’25. On Dec 03 ’25, another insider, FARRELL PETER C, who serves as the Director of the company, sold 2,000 shares for $251.47 each. As a result, the insider received 502,940 and left with 68,773 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RMD now has a Market Capitalization of 35404124160 and an Enterprise Value of 34866630656. As of this moment, Resmed’s Price-to-Earnings (P/E) ratio for their current fiscal year is 24.82, and their Forward P/E ratio for the next fiscal year is 20.05. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.76. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.73 while its Price-to-Book (P/B) ratio in mrq is 5.78. Its current Enterprise Value per Revenue stands at 6.632 whereas that against EBITDA is 17.987.
Stock Price History:
The Beta on a monthly basis for RMD is 0.88, which has changed by 0.036540627 over the last 52 weeks, in comparison to a change of 0.13329959 over the same period for the S&P500. Over the past 52 weeks, RMD has reached a high of $293.81, while it has fallen to a 52-week low of $199.92. The 50-Day Moving Average of the stock is -4.82%, while the 200-Day Moving Average is calculated to be -4.34%.
Shares Statistics:
For the past three months, RMD has traded an average of 1.04M shares per day and 910690 over the past ten days. A total of 145.94M shares are outstanding, with a floating share count of 145.05M. Insiders hold about 0.63% of the company’s shares, while institutions hold 65.94% stake in the company. Shares short for RMD as of 1764288000 were 10416904 with a Short Ratio of 9.98, compared to 1761868800 on 9690007. Therefore, it implies a Short% of Shares Outstanding of 10416904 and a Short% of Float of 8.2100004.
Dividends & Splits
According to the company, the forward annual dividend rate for RMD is 2.26, from 2.19 in the trailing year. Against a Trailing Annual Dividend Yield of 0.008904611. The stock’s 5-year Average Dividend Yield is 0.83. The current Payout Ratio is 22.30% for RMD, which recently paid a dividend on 2025-11-13 with an ex-dividend date of 2025-11-13. Stock splits for the company last occurred on 2010-08-31 when the company split stock in a 2:1 ratio.
Earnings Estimates
The company has 13.0 analysts who recommend its stock at the moment. The consensus estimate for the next quarter is $2.77, with high estimates of $2.86 and low estimates of $2.69.
Analysts are recommending an EPS of between $11.24 and $10.35 for the fiscal current year, implying an average EPS of $10.91. EPS for the following year is $12.03, with 19.0 analysts recommending between $12.66 and $11.63.
Revenue Estimates
A total of 16 analysts believe the company’s revenue will be $1.4B this quarter.It ranges from a high estimate of $1.43B to a low estimate of $1.36B. As of. The current estimate, Resmed Inc’s year-ago sales were $1.28BFor the next quarter, 16 analysts are estimating revenue of $1.41B. There is a high estimate of $1.44B for the next quarter, whereas the lowest estimate is $1.39B.
A total of 26 analysts have provided revenue estimates for RMD’s current fiscal year. The highest revenue estimate was $5.67B, while the lowest revenue estimate was $5.54B, resulting in an average revenue estimate of $5.6B. In the same quarter a year ago, actual revenue was $5.15BBased on 26 analysts’ estimates, the company’s revenue will be $6.02B in the next fiscal year. The high estimate is $6.17B and the low estimate is $5.91B.
